NCT06381778Recruiting
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis
Source: ClinicalTrials.gov · Last updated 26 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific "red-flag" signs of Fabry disease in Taiwan.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2600 (estimated)
- First submitted
- 19 Apr 2024
- Start date
- 6 Feb 2023
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Far Eastern Memorial Hospital
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06381778
What you commit to
- Study type: Observational
- Planned participants: 2600
- From 6 Feb 2023 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Athletic heart
Other
- Patients refuse or unable to give informed consent
- Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program
- Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload
- Non-compaction cardiomyopathy
Who the study is looking for
- Presence of left ventricular hypertrophy (LVH) on echo/CMRI:
- maximal interventricular septal (IVST) and/or posterior wall thickness (PWT) ≥13 mm,
- apical wall thickness ≥15 mm or a ratio of apical to basal LV wall thickness of ≥ 1.3 at end-diastole, OR
- maximal LV wall thickness ≥ 15mm of ANY OTHER PART
- Male and female adult age ≥ 20 year-old
- Patients willing to comply with and sign the informed consent
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Far Eastern Memorial Hospital Coordinator of this site? Confirm its status | New Taipei City | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.